Delivery Order SPE2DB22D1202-SPE2DB25FVLV7
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a ceiling value of $22,314. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of October 7, 2025. The contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,859.50 to AmerisourceBergen Drug Corp for the supply of Zoladex 10.8 mg implant syringes, with an ultimate completion date of August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively to the prime contractor. The place of performance is listed as Conshohocken, Pennsylvania, which is also the headquarters location of AmerisourceBergen Drug Corp, a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a contract ceiling value of $37,190. This is a firm fixed-price delivery order with an ultimate completion date of August 11, 2025, and represents a non-set-aside competitive award. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a ceiling value of $2,789.25. This is a firm fixed-price delivery order with an ultimate completion date of October 1, 2025, and represents a non-set-aside competitive award. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $9,297.50 to AmerisourceBergen Drug Corp for the supply of Zoladex 10.8 mg implant syringes. This contract, awarded on July 14, 2025, with an ultimate completion date of August 4, 2025, represents a firm fixed-price delivery order with no set-aside designation. The award was competitively procured and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zoladex is a hormone treatment used...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a ceiling value of $3,719.00 and ultimate completion date of October 1, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Zoladex 10.8 mg implant syringes under a firm fixed-price contract with a ceiling value of $7,564.32. The contract is scheduled for ultimate completion by August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and...
- The Defense Logistics Agency awarded a $5,578.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zoladex 10.8 mg implant syringes. The contract was competitively awarded without set-aside designation and carries an ultimate completion date of September 3, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania will serve as the place of performance for this pharmaceutical supply delivery. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $16,735.50 for Zoladex 10.8 mg implant syringes on August 8, 2025, with completion targeted for August 29, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $9,297.50 on August 12, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a completion date of September 3, 2025. This non-set-aside, competitively awarded contract carries firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVLV7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,789.25 to AmerisourceBergen Drug Corp for the supply of Zoladex 10.8 mg implant syringes. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of October 9, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a non-set-aside award, indicating the procurement was open to all qualified vendors. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December 2026. This prime vehicle serves as a comprehensive global pharmaceutical support contract enabling AmerisourceBergen to supply pharmaceutical products and medical commodities to support military healthcare programs worldwide. The current delivery order for Zoladex, a hormone treatment used in oncology and other therapeutic applications, exemplifies the company's role as a critical pharmaceutical distributor for the Defense Health Agency and other federal healthcare systems under the DLA's Medical Supply Chain procurement structure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 9/18/25 |